Shattuck Labs, Inc. (STTK)
STTKNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$4.99
+0.4000 (+8.71%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $508.19m
- P/E
- –
- EPS, last 4 quarters
- $-0.5100
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.72 to $8.33
- Average volume
- 1.20m
- Previous close
- $4.59
Analysts
9 coveringBuy9 buy, 0 hold, 0 sell
Targets a year out average $15.40, +208.6% from here
Earnings
next estimate $-0.1200Next report
Dec 2025
0.0%
Mar 2026
+7.1%
Jun 2026
+14.3%
Sep 2026
-40.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1.00m | – | – | – |
| Gross profit | $1.00m | – | – | – |
| Operating income | -$10.72m | -$13.37m | -$15.54m | -$16.15m |
| Net income | -$10.06m | -$12.59m | -$14.77m | -$15.15m |
News
8 latest- Shattuck Labs, Inc. Reports Third Quarter 2026 Financial Results and Initiates Phase 2b Trial of SL-325Fintel · 4 days ago
- Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Shattuck Advances SL-325 Into Phase 2 Hidradenitis Suppurativa Trial RTTNews · Oct 1, 2026
- What Shattuck Labs Stock Topped the Market on MondayThe Motley Fool · Aug 24, 2026
- Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?Zacks · Aug 20, 2026
- Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to TradeZacks · Aug 13, 2026
- Shattuck Labs Incurs Higher Q2 Loss; To Advance SL-325 In Phase 2b For Crohn's Disease In Q3 '26 RTTNews · Aug 11, 2026
- Why Shattuck Labs Stock Flew Nearly 5% Higher on FridayThe Motley Fool · Jul 24, 2026
The company
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck's expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 blocking antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- shattucklabs.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.